Nixon Peabody Trust Co. Buys 426 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Nixon Peabody Trust Co. raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.6% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 73,869 shares of the medical research company’s stock after purchasing an additional 426 shares during the period. IQVIA makes up approximately 1.5% of Nixon Peabody Trust Co.’s portfolio, making the stock its 21st biggest holding. Nixon Peabody Trust Co.’s holdings in IQVIA were worth $17,505,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. PGGM Investments lifted its position in shares of IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after buying an additional 4,326 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of IQVIA during the first quarter valued at about $3,365,000. Simplify Asset Management Inc. increased its holdings in shares of IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the period. Raymond James & Associates increased its stake in IQVIA by 0.7% in the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after acquiring an additional 5,417 shares during the last quarter. Finally, UniSuper Management Pty Ltd grew its holdings in shares of IQVIA by 253.0% during the first quarter. UniSuper Management Pty Ltd now owns 6,029 shares of the medical research company’s stock worth $1,525,000 after purchasing an additional 4,321 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on IQV shares. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research report on Friday, November 1st. Morgan Stanley cut their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft decreased their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. The Goldman Sachs Group lowered their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. cut their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $259.13.

IQVIA Stock Performance

Shares of NYSE:IQV traded up $0.18 during mid-day trading on Monday, reaching $192.86. 376,568 shares of the company traded hands, compared to its average volume of 1,138,689. The company’s 50 day moving average price is $226.95 and its 200-day moving average price is $228.24. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a market cap of $35.00 billion, a PE ratio of 25.29, a PEG ratio of 1.98 and a beta of 1.51. IQVIA Holdings Inc. has a 52 week low of $189.63 and a 52 week high of $261.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.